Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
At a glance
- Drugs Evacetrapib (Primary) ; Gemfibrozil
- Indications Atherosclerosis; Cardiovascular disorders; Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Jan 2013 New trial record